Statins do extend life expectancy for most people who take them. A large meta-analysis of matched studies found that statin users had roughly a 30% lower risk of dying from any cause compared to nonusers, and this benefit held for people both with and without existing heart disease. The size of that benefit in absolute terms, though, depends heavily on your age, your baseline risk, and how long you take the medication.
How Much Longer Statins Help You Live
The honest answer is: it depends on who you are. Relative risk reductions sound impressive, but the absolute gains vary widely. In the landmark West of Scotland trial, which studied people without heart disease, total mortality over about five years was 3.2% in the statin group versus 4.1% in the placebo group. That’s a real but modest absolute difference of less than 1 percentage point. In the Heart Protection Study, which included higher-risk patients, the gap was larger: 12.9% versus 14.7% over a similar period.
For people who have already had a heart attack, the picture is more concrete but still sobering in absolute terms. A study of nursing home residents who started statins after a heart attack found that the medication added an average of about 16 days of survival over one year of follow-up. That number sounds small, but it reflects a population with very limited life expectancy to begin with. In younger, healthier people with established heart disease, the cumulative benefit over years of treatment is substantially larger.
The core principle: the higher your cardiovascular risk, the more life a statin is likely to add. People with a high baseline risk score see meaningfully greater absolute reductions than those at low risk, even though the relative reduction is similar across groups.
Benefits for People Without Heart Disease
This is where the debate gets sharpest. Statins are widely prescribed for “primary prevention,” meaning people who haven’t had a heart attack or stroke but have risk factors like high cholesterol, diabetes, or high blood pressure. The evidence supports a real mortality benefit in this group, but it takes time to materialize.
A meta-analysis published in JAMA Internal Medicine examined how long primary prevention patients needed to take statins before a survival benefit appeared. For reducing major cardiovascular events, the time to benefit was roughly 0.8 years for every 500 patients treated. For all-cause mortality specifically, the two trials that showed a clear benefit required between 1.5 and 3 years before the survival curves separated. In practical terms, this means statins aren’t a quick fix. If your life expectancy is less than two to three years for other reasons, a new statin prescription is unlikely to extend your life.
For every 39 mg/dL drop in LDL cholesterol (a standard benchmark), cardiovascular death risk falls by about 15%. But this effect is stronger when your starting cholesterol is higher. If your LDL is already borderline, the same medication produces a smaller absolute payoff.
Statins After Age 75
One of the most common questions is whether older adults should start statins if they’ve never taken them. A large Veterans Administration study tracked nearly 327,000 veterans aged 75 to 107, none of whom had heart disease or prior statin use at the start. About 57,000 of them began taking statins during the study period.
New statin users had a 25% lower risk of dying from any cause and a 20% lower risk of dying from heart disease compared to nonusers. Notably, the benefit remained significant even in veterans over 90 and in those with dementia. A large National Institutes of Health trial called PREVENTABLE, enrolling 20,000 adults 75 and older, is expected to provide more definitive answers when it wraps up.
Do Statins Work Equally for Women and Men?
Yes. A meta-analysis of 18 randomized trials published in the Journal of the American College of Cardiology found that statins reduced cardiovascular events by about 19% in women and 23% in men, with no statistically significant difference between the sexes. All-cause mortality was also lower with statin therapy in both women and men, with no meaningful interaction by sex. Earlier concerns that statins were less effective in women stemmed from smaller sample sizes in older trials rather than a genuine biological difference.
The Diabetes Trade-Off
Statins do carry a real side effect that’s relevant to longevity: they increase the risk of developing type 2 diabetes. High-intensity statin therapy raises diabetes risk by about 36% compared to placebo. That sounds alarming in isolation, but the math still favors statins for most people. The cardiovascular protection, which directly prevents heart attacks, strokes, and death, substantially outweighs the added diabetes risk in people who meet guideline criteria for treatment. For someone already on the borderline of diabetes with low cardiovascular risk, though, this trade-off becomes a more meaningful part of the conversation.
Who Benefits Most, and Who Benefits Least
The clearest beneficiaries are people who have already had a heart attack or stroke. For them, the evidence for extended survival is strong and consistent. Next in line are people without heart disease but with significant risk factors, particularly those with high LDL cholesterol, diabetes, or a 10-year cardiovascular risk above 10%. Adults over 75 appear to benefit even when starting for the first time, though the absolute gains are smaller when life expectancy is already limited.
The benefit is smallest for young, low-risk individuals with mildly elevated cholesterol and no other risk factors. Statins still lower their cholesterol effectively, but because their baseline chance of dying from heart disease in the next decade is already very low, the absolute life expectancy gain is minimal. This is the group where lifestyle changes like diet, exercise, and weight management offer the most favorable risk-to-reward ratio before adding medication.
The bottom line is that statins genuinely extend life for millions of people, but they’re not a uniform addition of X years for everyone. Your personal benefit scales with your personal risk. The higher your starting risk of cardiovascular death, the more days, months, or years a statin is likely to add.